4 results on '"virus pandemics"'
Search Results
2. Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs.
- Author
-
Tompa, Dharma Rao, Immanuel, Aruldoss, Srikanth, Srimari, and Kadhirvel, Saraboji
- Subjects
- *
ANTIVIRAL agents , *VIRUS diseases , *NUCLEOSIDE reverse transcriptase inhibitors , *EMERGING infectious diseases , *INTERFERON receptors , *INTEGRASE inhibitors - Abstract
The infectious microscopic viruses invade living cells to reproduce themselves, and causes chronic infections such as HIV/AIDS, hepatitis B and C, flu, etc. in humans which may lead to death if not treated. Different strategies have been utilized to develop new and superior antiviral drugs to counter the viral infections. The FDA approval of HIV nucleoside reverse transcriptase inhibitor, zidovudine in 1987 boosted the development of antiviral agents against different viruses. Currently, there are a number of combination drugs developed against various viral infections to arrest the activity of same or different viral macromolecules at multiple stages of its life cycle; among which majority are targeted to interfere with the replication of viral genome. Besides these, other type of antiviral molecules includes entry inhibitors, integrase inhibitors, protease inhibitors, interferons, immunomodulators, etc. The antiviral drugs can be toxic to human cells, particularly in case of administration of combination drugs, and on the other hand viruses can grow resistant to the antiviral drugs. Furthermore, emergence of new viruses like Ebola, coronaviruses (SARS-CoV, SARS-CoV-2) emphasizes the need for more innovative strategies to develop better antiviral drugs to fight the existing and the emerging viral infections. Hence, we reviewed the strategic enhancements in developing antiviral drugs for the treatment of different viral infections over the years. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. What is life? A perspective of the mathematical kinetic theory of active particles
- Author
-
Pietro Terna, Nicola Bellomo, Giovanni Dosi, Diletta Burini, Livio Gibelli, Nisrine Outada, Damián Alejandro Knopoff, Maria Enrica Virgillito, University of Granada [Granada], Università degli Studi di Perugia (UNIPG), Scuola Universitaria Superiore Sant'Anna [Pisa] (SSSUP), University of Edinburgh, Basque Center for Applied Mathematics (BCAM), Basque Center for Applied Mathematics, Université Cadi Ayyad [Marrakech] (UCA), Unité de modélisation mathématique et informatique des systèmes complexes [Bondy] (UMMISCO), Institut de Recherche pour le Développement (IRD [France-Nord])-Institut de la francophonie pour l'informatique-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Université Gaston Bergé (Saint-Louis, Sénégal)-Université Cadi Ayyad [Marrakech] (UCA)-Université de Yaoundé I-Sorbonne Université (SU), Università degli studi di Torino (UNITO), Universidad de Granada = University of Granada (UGR), Università degli Studi di Perugia = University of Perugia (UNIPG), Université de Yaoundé I-Institut de la francophonie pour l'informatique-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Université Gaston Bergé (Saint-Louis, Sénégal)-Université Cadi Ayyad [Marrakech] (UCA)-Sorbonne Université (SU)-Institut de Recherche pour le Développement (IRD [France-Nord]), and Università degli studi di Torino = University of Turin (UNITO)
- Subjects
Crowd dynamics ,Computer science ,virus pandemics ,01 natural sciences ,Active particles ,0103 physical sciences ,92D30 ,evolutionary economics ,multiscale problems ,Statistical physics ,0101 mathematics ,[MATH]Mathematics [math] ,010306 general physics ,Applied Mathematics ,Perspective (graphical) ,virus pandemic ,collective learning ,Collaborative learning ,Living systems ,010101 applied mathematics ,92C60 ,Modeling and Simulation ,Kinetic theory of gases ,kinetic theory ,Evolutionary economics ,crowd dynamics ,complexity - Abstract
International audience; The modeling of living systems composed of many interacting entities is treated in this paper with the aim of describing their collective behaviors. The mathematical approach is developed within the general framework of the kinetic theory of active particles. The presentation is in three parts. First, we derive the mathematical tools, subsequently, we show how the method can be applied to a number of case studies related to well defined living systems, and finally, we look ahead to research perspectives.
- Published
- 2021
- Full Text
- View/download PDF
4. Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs
- Author
-
Srimari Srikanth, Dharma Rao Tompa, Aruldoss Immanuel, and Saraboji Kadhirvel
- Subjects
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,medicine.medical_treatment ,viruses ,Integrase inhibitor ,02 engineering and technology ,Review ,Biochemistry ,Antiviral Agents ,Nucleoside Reverse Transcriptase Inhibitor ,03 medical and health sciences ,Zidovudine ,Acquired immunodeficiency syndrome (AIDS) ,Structural Biology ,Pandemic ,Virus pandemics ,medicine ,Humans ,Molecular Biology ,Drug Approval ,Pandemics ,030304 developmental biology ,0303 health sciences ,Protease ,business.industry ,United States Food and Drug Administration ,Antiviral drugs ,General Medicine ,Hepatitis B ,Protease inhibitors ,021001 nanoscience & nanotechnology ,medicine.disease ,Virology ,United States ,NRTIs ,Virus Diseases ,NNRTIs ,Combination therapies ,0210 nano-technology ,business ,Entry inhibitors ,medicine.drug - Abstract
The infectious microscopic viruses invade living cells to reproduce themselves, and causes chronic infections such as HIV/AIDS, hepatitis B and C, flu, etc. in humans which may lead to death if not treated. Different strategies have been utilized to develop new and superior antiviral drugs to counter the viral infections. The FDA approval of HIV nucleoside reverse transcriptase inhibitor, zidovudine in 1987 boosted the development of antiviral agents against different viruses. Currently, there are a number of combination drugs developed against various viral infections to arrest the activity of same or different viral macromolecules at multiple stages of its life cycle; among which majority are targeted to interfere with the replication of viral genome. Besides these, other type of antiviral molecules includes entry inhibitors, integrase inhibitors, protease inhibitors, interferons, immunomodulators, etc. The antiviral drugs can be toxic to human cells, particularly in case of administration of combination drugs, and on the other hand viruses can grow resistant to the antiviral drugs. Furthermore, emergence of new viruses like Ebola, coronaviruses (SARS-CoV, SARS-CoV-2) emphasizes the need for more innovative strategies to develop better antiviral drugs to fight the existing and the emerging viral infections. Hence, we reviewed the strategic enhancements in developing antiviral drugs for the treatment of different viral infections over the years.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.